Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. Yurkiewicz IR, Coutre S, Ghesquieres H, Pastan I, et al. Leuk Lymphoma 2021 May 25:1-3. doi: 10.1080/10428194.2021.1929959.

Read + Share

Amedeo Smart

Independent Medical Education

Yurkiewicz IR, Coutre S, Ghesquieres H, Pastan I, et al. Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. Leuk Lymphoma 2021 May 25:1-3. doi: 10.1080/10428194.2021.1929959.
PMID: 34030585